1Building the leading Swiss healthcare platform over 90 years
CorporateServicesRetailProducts & Brands
1History of resilient growth and margin improvement
70% c.4'944
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
Net sales (CHFm)EBIT margin %
Source:
Company information, Galenica Annual Reports, IQVIA (former IMS Health)
Notes:
The financial information presented with respect to the financial years ended 31 December 2007 through 2013 has been derived from the audited consolidated financial statements of Galenica AG (now renamed Vifor Pharma
AG) and represent its Logistics, Retail and Other (Healthcare Information) businesses, excluding the Pharma business. The Company, a former wholly-owned subsidiary of Galenica AG (now renamed Vifor Pharma AG),
prepared combined financial statements for the financial years ended 31 December 2014, 2015 and 2016. Accordingly, the financial information derived from the combined financial statements of the Company and from the
consolidated financials of Galenica AG (now Vifor Pharma AG) for its Logistics, Retail and Other (Healthcare Information) businesses, excluding the Pharma business, for prior periods may not be fully comparable.
1
Not including Vifor Consumer Health
2
Retail market sales include direct and indirect pharmaceutical sales through pharmacies, self-dispensing doctors and drugstores
3
2014-16 EBIT from combined financial statements and 2017 EBIT, excludes IAS 19 expense
4
2013 financials as per 2014 financial statements due to changed segment structure (Galenica Santé is reported as a separate segment since 2014). Financials not adjusted to include Products & Brands
5
Calculated as (EBITDA-capex)/EBITDA. 2014-17 EBITDA excludes IAS 19 adjustment; capex includes investments in tangible and intangible assets
17 April 2017: Outstanding IPO of Galenica Santé
Largest IPO in Europe in H1 2017 and first sizeable 100% subsidiary IPO since years
Multiple oversubscription with pricing at the top end of the price range at
CHF 39.00
Broadly diversified allocation
Today already about 14'000 shareholders
Strong and stable trading after IPO
1) Allocation of the shares at the IPO on 7 April 2017
Attachments
Original document
Permalink
Disclaimer
Galenica AG published this content on 08 August 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 08 August 2018 13:13:04 UTC
Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
GALENICA AG 
